aTyr Pharma (NASDAQ:ATYR) Given Market Perform Rating at Leerink Partners

aTyr Pharma (NASDAQ:ATYR)‘s stock had its “market perform” rating restated by stock analysts at Leerink Partners in a note issued to investors on Monday, Marketbeat reports.

ATYR has been the topic of several other reports. Wall Street Zen lowered shares of aTyr Pharma from a “hold” rating to a “sell” rating in a report on Saturday, August 9th. HC Wainwright reaffirmed a “buy” rating and set a $35.00 target price on shares of aTyr Pharma in a research note on Wednesday, June 4th. Jefferies Financial Group upped their target price on shares of aTyr Pharma from $9.00 to $17.00 and gave the stock a “buy” rating in a research note on Friday, August 22nd. Cantor Fitzgerald downgraded shares of aTyr Pharma from an “overweight” rating to a “neutral” rating in a research note on Monday. Finally, Wells Fargo & Company upped their target price on shares of aTyr Pharma from $17.00 to $25.00 and gave the stock an “overweight” rating in a research note on Friday, June 20th. One research analyst has rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, aTyr Pharma has a consensus rating of “Hold” and an average target price of $23.25.

aTyr Pharma Stock Performance

NASDAQ:ATYR opened at $1.08 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.63 and a quick ratio of 5.63. The firm has a market capitalization of $105.83 million, a price-to-earnings ratio of -1.35 and a beta of 1.01. The company’s 50-day moving average is $5.20 and its two-hundred day moving average is $4.34. aTyr Pharma has a 1-year low of $1.00 and a 1-year high of $7.29.

aTyr Pharma (NASDAQ:ATYR) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.04). Analysts forecast that aTyr Pharma will post -0.91 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ATYR. Group One Trading LLC purchased a new position in shares of aTyr Pharma in the 4th quarter valued at $26,000. California State Teachers Retirement System purchased a new position in shares of aTyr Pharma in the 2nd quarter valued at $28,000. Y Intercept Hong Kong Ltd purchased a new position in shares of aTyr Pharma in the 1st quarter valued at $38,000. Two Sigma Advisers LP purchased a new position in shares of aTyr Pharma in the 4th quarter valued at $44,000. Finally, Ameritas Investment Partners Inc. purchased a new position in shares of aTyr Pharma in the 2nd quarter valued at $45,000. 61.72% of the stock is owned by hedge funds and other institutional investors.

About aTyr Pharma

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.